Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Transform Your Health: WHO Endorses Gilead’s Revolutionary Twice-Yearly Injection for HIV Prevention!
News

Transform Your Health: WHO Endorses Gilead’s Revolutionary Twice-Yearly Injection for HIV Prevention!

By adminitfy
July 15, 2025 2 Min Read

The World Health Organization (WHO) has officially endorsed Gilead’s lenacapavir as a powerful new tool in the prevention of HIV infection. This recommendation was unveiled at the International AIDS Conference held in Kigali, Rwanda, and it comes on the heels of the recent approval by U.S. health regulators, igniting fresh optimism among patients seeking methods to halt the transmission of the virus.

Lenacapavir is a breakthrough injectable treatment administered twice a year, offering a long-acting alternative to daily oral medications, which can present challenges for many. The availability of this injection aims to transform the landscape of HIV prevention, particularly benefitting individuals who struggle with daily adherence, face stigma, or encounter difficulties accessing healthcare services.

“While an HIV vaccine remains elusive, lenacapavir is the next best thing,” remarked Dr. Tedros Adhanom Ghebreyesus, WHO’s Director-General. This endorsement comes at a pivotal time when efforts to curb HIV infections have hit a plateau, with the WHO projecting approximately 1.3 million new cases in 2024 due to ongoing funding shortfalls and persistent social stigma.

Certain populations remain disproportionately affected by HIV, including sex workers, men who have sex with men, transgender individuals, people who inject drugs, those incarcerated, and children and adolescents. The WHO’s recommendation is thus not only timely but also essential for enhancing prevention strategies tailored to these vulnerable groups.

In addition to the endorsement of lenacapavir, the WHO is advocating for a public health approach to HIV testing. This would involve the use of rapid HIV tests, effectively removing significant barriers to access by simplifying procedures that have often been complex and costly.

Lenacapavir falls within a promising class of drugs referred to as capsid inhibitors. In extensive clinical trials conducted last year, it demonstrated nearly 100% efficacy in preventing HIV transmission, reinforcing its potential role in a comprehensive HIV prevention strategy.

As global health efforts adapt to the evolving landscape of HIV/AIDS, lenacapavir represents a critical advancement, giving individuals renewed hope in managing and preventing the virus. By shifting away from daily oral medication regimens, it promises to ease the burden of adherence, address stigma, and enhance overall access to crucial preventive care.

With these advancements, the worldwide health community is reminded of the pressing need for sustained investment in HIV prevention, treatment, and education initiatives. As lenacapavir becomes part of this conversation, it not only highlights scientific progress but also the ongoing challenges and inequalities that persist in the fight against HIV.

As efforts continue to address the HIV epidemic, the introduction of lenacapavir may prove to be a game changer, offering a beacon of hope for millions seeking effective ways to prevent HIV infection.

[Categories: Health, HIV, WHO, Medicine, Innovation]
[Tags: HIV prevention, lenacapavir, WHO recommendations, AIDS Conference, healthcare access]

Original Source: https://m.economictimes.com/news/international/world-news/who-recommends-gileads-twice-yearly-injection-for-hiv-prevention/articleshow/122460053.cms
Category :
Tags:
Publish Date: 2025-07-15 00:47:00

Author

adminitfy

Follow Me
Other Articles
Previous

For regions like Assam, embracing AI presents a unique opportunity to bridge the gap between global technological advancements and regional development. By integrating AI into sectors such as agriculture, education, and healthcare, Assam can enhance productivity, improve service delivery, and foster inclusive growth. However, this integration must be approached thoughtfully, ensuring that the benefits of AI are equitably distributed and that local communities are equipped with the necessary skills to thrive in an AI-driven economy.

Next

Manipur Unveils Innovative IDP Portal to Enhance Relief for Displaced Persons

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • ডাউদ ঘনিষ্ঠ গেংষ্টাৰ নাছিম দুৰানী ‘এনকাউণ্টাৰ’ত নিহত, ২৫টা গোচৰত অভিযুক্ত
    ডাউদ ঘনিষ্ঠ গেংষ্টাৰ নাছিম দুৰানী ‘এনকাউণ্টাৰ’ত নিহত, ২৫টা গোচৰত অভিযুক্ত
    by adminitfy
    November 20, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • ডাউদ ঘনিষ্ঠ গেংষ্টাৰ নাছিম দুৰানী ‘এনকাউণ্টাৰ’ত নিহত, ২৫টা গোচৰত অভিযুক্ত
  • Manipur MLA Sapam Kunjakeshwor Singh Dies, Mortal Remains Arrive Today
  • The Premium Nostalgia Trap: Why Delight Is Not a Demand Strategy
  • ৰোহিংগীয়া নিৰ্বিচাৰ হত্যা: ম্যানমাৰ দায়ী, আন্তঃৰাষ্ট্ৰীয় ন্যায়ালয়ে কি ক’লে?
  • Horoscope Today, November 20, 2026: Astrological Predictions Revealed
  • November 2026 (618)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.